NR AFEF
AU Harrison,P.J.; Barton,A.J.; Najlerahim,A.; McDonald,B.; Pearson,R.C.
TI Regional and neuronal reductions of polyadenylated messenger RNA in Alzheimer's disease
QU Psychological Medicine 1991 Nov; 21(4): 855-66
PT journal article
AB Messenger RNA (mRNA) is the key intermediate in the gene expression pathway. The amount of mRNA in Alzheimer's disease (AD) brains has been determined using in situ hybridization histochemistry (ISHH) to detect the poly(A) tails of polyadenylated mRNA (poly(A) + mRNA). On a regional basis, AD cases had significantly less poly(A) + mRNA than controls in hippocampus (field CA3) and cerebellum (granule cell layer). Analysis of constituent pyramidal neurons showed mean reductions per cell within AD hippocampus (field CA3) and temporal cortex, but not in visual cortex. Similar changes were seen in a small group of non-AD dementias. The finding of reduced poly(A) + mRNA content is another indication of the altered brain gene expression occurring in AD. It is proposed that measurement of poly(A) + mRNA may be valuable in identifying functionally impaired neuronal populations. The methodology also provides a means by which changes in the quantitative distribution of individual mRNAs can be determined relative to that of poly(A) + mRNA as a whole.
MH Adult; Aged; Aged, 80 and over; Alzheimer Disease/*genetics/*pathology; Brain/*pathology; Brain Mapping; Cerebellum/pathology; Dementia/genetics/pathology; Female; Gerstmann-Sträussler-Scheinker Disease/genetics/pathology; Hippocampus/pathology; Human; Huntington Disease/genetics/pathology; Male; Middle Age; Neurons/pathology; Nucleic Acid Hybridization; Poly A/*analysis/*genetics; RNA, Messenger/*analysis/*genetics; Support, Non-U.S. Gov't; Temporal Lobe/pathology; Transcription, Genetic/*genetics; Visual Cortex/pathology
AD Department of Anatomy, St Mary's Hospital Medical School, London.
SP englisch
PO England